Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone

Summary

Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM. The overall response rate was 71% including complete remission of 15%. Median progression free survival and overall survival were 8.9 and 30.5 months. In addition, grade 3-4 toxicities such as neutropenia, and infections were reduced. This study supported that lower dose lenalidomide may be optimal stating dose for elderly patients with frailty.

Timeline

Start

2019-03-11

Primary completion

2024-12-31

Completion

2025-12-31

Drugs

Indications